Denali Therapeutics price target lowered to $27 from $28 at BofA

BofA analyst Tazeen Ahmad lowered the firm’s price target on Denali Therapeutics (DNLI) to $27 from $28 and keeps a Buy rating on the shares. Denali announced they have completed the biologics license application for tividenofusp alfa for Hunter Syndrome and noted the application was submitted under the accelerated approval path, the analyst tells investors. The firm updated its model for Q1 results, cash and share count and increase op expense estimates in line with trend and slightly pushed its near-term estimates for tivi’ as it expects a launch in early 2026, the analyst noted.